azacitidine pharmascience 25 mg/ml proszek do sporządzania zawiesiny do wstrzykiwań
pharmascience international limited - azacitidinum - proszek do sporządzania zawiesiny do wstrzykiwań - 25 mg/ml
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Środki przeciwnowotworowe - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - chlorowodorek klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - Środki przeciwzakrzepowe - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
bortezomib pharmaswiss 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
pharmaswiss Česká republika s.r.o. - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg
dabigatran etexilate +pharma 75 mg kapsułki twarde
+pharma arzneimittel gmbh - dabigatranu eteksylan w postaci mezylanu - kapsułki twarde - 75 mg
dabigatran etexilate +pharma 150 mg kapsułki twarde
+pharma arzneimittel gmbh - dabigatranu eteksylan w postaci mezylanu - kapsułki twarde - 150 mg
rivastigmine 3m health care ltd
3m health care limited - rywastygmina - choroba alzheimera - psychoanaleptics, , cholinoesterazy - objawowe leczenie łagodnej i średnio zaawansowanej postaci alzheimera.
amlodipine + atorvastatin polpharma 10 mg + 10 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - amlodipini besilas + atorvastatinum calcicum trihydricum - tabletki powlekane - 10 mg + 10 mg
amlodipine + atorvastatin polpharma 5 mg + 20 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - amlodipini besilas + atorvastatinum calcicum trihydricum - tabletki powlekane - 5 mg + 20 mg
amlodipine + atorvastatin polpharma 10 mg + 20 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - amlodipini besilas + atorvastatinum calcicum trihydricum - tabletki powlekane - 10 mg + 20 mg